Skip to main content

Atlas Venture Fund XI, L.P.'s Form 4 filing

ImageneBio, Inc. (IMA) · filed Dec 14, 2021

Accession no.
0001209191-21-069644
Filed
Dec 14, 2021, 8:27 PM ET
Trade date
Mar 30-Dec 14, 2021
Filing delay
259 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions. Open-market purchases total $2.00M. Open-market sales total $385.6K. It was filed 259 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Atlas Venture Fund XI, L.P.CIK 000170826910% Owner
Atlas Venture Opportunity Fund I, L.P.CIK 000175924110% Owner
Atlas Venture Associates Opportunity I, L.P.CIK 000178006510% Owner
Atlas Venture Associates Opportunity I, LLCCIK 000178006610% Owner
Atlas Venture Associates XI, LLCCIK 000178006710% Owner
Atlas Venture Associates XI, L.P.CIK 000178006810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 30, 2021Common StockPPurchaseAcquired+125,000$16.00+$2,000,000874,634IndirectDuplicate filing
Dec 10, 2021Common StockSSaleDisposed−11,989$15.03F2−$180,194.671,256,224DirectDuplicate filing
Dec 13, 2021Common StockSSaleDisposed−8,330$14.64F4−$121,951.21,247,894DirectDuplicate filing
Dec 14, 2021Common StockSSaleDisposed−5,959$14.00−$83,4261,241,935DirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)